EA202091433A1 - Новые производные бензамида в качестве модуляторов ppar-гамма - Google Patents
Новые производные бензамида в качестве модуляторов ppar-гаммаInfo
- Publication number
- EA202091433A1 EA202091433A1 EA202091433A EA202091433A EA202091433A1 EA 202091433 A1 EA202091433 A1 EA 202091433A1 EA 202091433 A EA202091433 A EA 202091433A EA 202091433 A EA202091433 A EA 202091433A EA 202091433 A1 EA202091433 A1 EA 202091433A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diseases
- ppar
- benzamide derivatives
- new benzamide
- gamma modulators
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 150000003936 benzamides Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Настоящее изобретение относится к новым производным бензамида формулы (I) в качестве модуляторов PPAR-гамма рецептора, способам их получения, фармацевтическим композициям, содержащим указанные соединения, и к применению указанного соединения в лечении патологических состояний, расстройств или заболеваний, которые могут облегчаться модуляцией PPAR-гамма рецептора, таких как рак, метаболические заболевания, воспалительные заболевания, нарушения со стороны дыхательной системы, аутоиммунные заболевания, нейродегенеративные заболевания, сердечно-сосудистые заболевания и заболевания почек.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382845.0A EP3498694A1 (en) | 2017-12-12 | 2017-12-12 | New benzamide derivatives as ppar-gamma modulators |
| PCT/EP2018/084290 WO2019115498A1 (en) | 2017-12-12 | 2018-12-11 | New benzamide derivatives as ppar-gamma modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091433A1 true EA202091433A1 (ru) | 2020-09-09 |
Family
ID=60673764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091433A EA202091433A1 (ru) | 2017-12-12 | 2018-12-11 | Новые производные бензамида в качестве модуляторов ppar-гамма |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11267808B2 (ru) |
| EP (2) | EP3498694A1 (ru) |
| JP (1) | JP7212235B2 (ru) |
| KR (1) | KR102688870B1 (ru) |
| CN (1) | CN111630030B (ru) |
| AU (1) | AU2018382461B2 (ru) |
| BR (1) | BR112020011558A2 (ru) |
| CA (1) | CA3084879A1 (ru) |
| CY (1) | CY1125060T1 (ru) |
| DK (1) | DK3724165T3 (ru) |
| EA (1) | EA202091433A1 (ru) |
| ES (1) | ES2908938T3 (ru) |
| HR (1) | HRP20220329T1 (ru) |
| HU (1) | HUE058004T2 (ru) |
| LT (1) | LT3724165T (ru) |
| MX (1) | MX2020006235A (ru) |
| PL (1) | PL3724165T3 (ru) |
| PT (1) | PT3724165T (ru) |
| RS (1) | RS63021B1 (ru) |
| SI (1) | SI3724165T1 (ru) |
| WO (1) | WO2019115498A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021092262A1 (en) * | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Mrgprx2 antagonists and uses thereof |
| KR20230107291A (ko) * | 2020-11-09 | 2023-07-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | PPARγ 조절제 및 사용 방법 |
| CN113350346B (zh) * | 2021-06-01 | 2023-06-27 | 广西医科大学第一附属医院 | 长春新碱在预防或治疗心肌纤维化中的应用 |
| AU2023231613A1 (en) * | 2022-03-08 | 2024-09-05 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| WO2023172846A1 (en) * | 2022-03-08 | 2023-09-14 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| WO2023219879A1 (en) * | 2022-05-09 | 2023-11-16 | Eisai R&D Management Co., Ltd. | SOLID FORM OF PPAR-gamma MODULATORS AND METHODS OF USE |
| CN115160341B (zh) * | 2022-07-18 | 2023-07-18 | 中国医学科学院医学实验动物研究所 | 苯并噁嗪类化合物及其药物用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| PL357678A1 (en) * | 2000-04-28 | 2004-07-26 | Sankyo Company, Limited | Ppargamma modulators |
| JP2003073357A (ja) * | 2001-09-03 | 2003-03-12 | Mitsubishi Pharma Corp | アミド化合物を含有するＲｈｏキナーゼ阻害剤 |
| US20080206194A1 (en) * | 2007-02-16 | 2008-08-28 | Glazer Robert I | Method for the treatment of breast cancer |
| US8686048B2 (en) * | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| CN104302627A (zh) * | 2012-05-22 | 2015-01-21 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的嘧啶化合物 |
-
2017
- 2017-12-12 EP EP17382845.0A patent/EP3498694A1/en not_active Withdrawn
-
2018
- 2018-12-11 HU HUE18812195A patent/HUE058004T2/hu unknown
- 2018-12-11 EP EP18812195.8A patent/EP3724165B1/en active Active
- 2018-12-11 RS RS20220183A patent/RS63021B1/sr unknown
- 2018-12-11 MX MX2020006235A patent/MX2020006235A/es unknown
- 2018-12-11 KR KR1020207018762A patent/KR102688870B1/ko active IP Right Grant
- 2018-12-11 BR BR112020011558-4A patent/BR112020011558A2/pt unknown
- 2018-12-11 LT LTEPPCT/EP2018/084290T patent/LT3724165T/lt unknown
- 2018-12-11 HR HRP20220329TT patent/HRP20220329T1/hr unknown
- 2018-12-11 AU AU2018382461A patent/AU2018382461B2/en active Active
- 2018-12-11 EA EA202091433A patent/EA202091433A1/ru unknown
- 2018-12-11 ES ES18812195T patent/ES2908938T3/es active Active
- 2018-12-11 DK DK18812195.8T patent/DK3724165T3/da active
- 2018-12-11 CN CN201880087036.4A patent/CN111630030B/zh active Active
- 2018-12-11 US US16/771,514 patent/US11267808B2/en active Active
- 2018-12-11 JP JP2020532042A patent/JP7212235B2/ja active Active
- 2018-12-11 PT PT188121958T patent/PT3724165T/pt unknown
- 2018-12-11 CA CA3084879A patent/CA3084879A1/en active Pending
- 2018-12-11 PL PL18812195T patent/PL3724165T3/pl unknown
- 2018-12-11 WO PCT/EP2018/084290 patent/WO2019115498A1/en unknown
- 2018-12-11 SI SI201830623T patent/SI3724165T1/sl unknown
-
2022
- 2022-03-09 CY CY20221100197T patent/CY1125060T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102688870B1 (ko) | 2024-07-25 |
| US20210171511A1 (en) | 2021-06-10 |
| EP3724165B1 (en) | 2022-01-12 |
| RS63021B1 (sr) | 2022-04-29 |
| JP7212235B2 (ja) | 2023-01-25 |
| KR20200098557A (ko) | 2020-08-20 |
| PL3724165T3 (pl) | 2022-04-25 |
| EP3498694A1 (en) | 2019-06-19 |
| CN111630030B (zh) | 2023-06-20 |
| PT3724165T (pt) | 2022-04-06 |
| SI3724165T1 (sl) | 2022-06-30 |
| MX2020006235A (es) | 2020-08-24 |
| JP2021505641A (ja) | 2021-02-18 |
| DK3724165T3 (da) | 2022-02-21 |
| US11267808B2 (en) | 2022-03-08 |
| CY1125060T1 (el) | 2023-06-09 |
| AU2018382461A1 (en) | 2020-07-09 |
| ES2908938T3 (es) | 2022-05-04 |
| LT3724165T (lt) | 2022-03-25 |
| CN111630030A (zh) | 2020-09-04 |
| BR112020011558A2 (pt) | 2020-12-08 |
| CA3084879A1 (en) | 2019-06-20 |
| HRP20220329T1 (hr) | 2022-05-13 |
| AU2018382461B2 (en) | 2023-04-27 |
| EP3724165A1 (en) | 2020-10-21 |
| HUE058004T2 (hu) | 2022-06-28 |
| WO2019115498A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091433A1 (ru) | Новые производные бензамида в качестве модуляторов ppar-гамма | |
| PH12017501339A1 (en) | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof | |
| EA201690316A1 (ru) | Соединения для применения в качестве иммуномодуляторов | |
| EA201792047A1 (ru) | Новые соединения | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| EA201991183A1 (ru) | Новые ингибиторы глутаминазы | |
| EA201592143A1 (ru) | Новые бициклические ингибиторы бромодомена | |
| EA201792548A1 (ru) | 4-гидрокси-3-(гетероарил)пиридин-2-оновые агонисты apj для применения в лечении сердечно-сосудистых заболеваний | |
| EA201691514A1 (ru) | Соединения | |
| EA201691940A1 (ru) | Новые соединения | |
| EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
| EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| EA201491973A1 (ru) | Новые соединения | |
| EA201891799A1 (ru) | Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda | |
| EA201890245A1 (ru) | Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b | |
| EA201790688A1 (ru) | Новые соединения в качестве ингибиторов nik | |
| EA201790904A1 (ru) | Новые производные пиразола в качестве ингибиторов nik | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| EA201790908A1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| EA201790907A1 (ru) | Новые производные пиразолопиримидина в качестве ингибиторов nik |